Future Directions in Pulmonary Arterial Hypertension: Novel Treatment Pathways, Evolving Treatment Paradigms, Addressing Differences in SDoH
Nicholas Kolaitis, MD, MAS
Pulmonary, Critical Care, Allergy and Sleep Medicine
University of California at San Francisco
San Francisco, CA
Sandhya Murthy, MD
Department of Medicine,
Advanced Heart Failure and Transplantation
Albert Einstein College of Medicine
Director, Pulmonary Hypertension CenterCo-Director, Heart Failure Center in Nyack Hospital
Upon completion of this activity, the participant should be able to:
•Evaluate the latest clinical trial data on emerging PAH therapies furthest along in late-stage clinical trials and discuss their potential role in the treatment landscape based on available studies
Physician Accreditation Statement
Physician Credit Designation
Instructions to Receive Credit
- Read the learning objectives and faculty disclosures Complete the pretest
- View the broadcast
- Complete the posttest with a score of 70% or higher
A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.
Fee Information and Refund/Cancellation Policy
Disclosures of Relevant Financial Relationships
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Sandhya Murthy, MD
The following planners and managers involved in the development of this activity have no relevant financial relationships with ineligible companies to disclose.
Disclosure of Unlabeled Use
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.